Dizlin Pharmaceuticals announces the appointment of Daniel Mackey as Chief Financial Officer (CFO) effective as of November 1, 2021.

Daniel Mackey brings to Dizlin Pharmaceuticals more than 20 years of finance and controlling experience. Prior to joining the company, Daniel has a background in the finance and life science sector. He has held senior management positions at Nordea in Stockholm, Investors Trust Ireland in Dublin, and most recently the CFO position at Infant Bacterial Therapeutics AB, a pharmaceutical company listed on Nasdaq Stockholm. He holds a BS, Economics from State University of New York College at Plattsburgh, in the US.

“I am pleased to announce that Daniel Mackey has joined our Executive Management Team as CFO. Daniel’s competence, extensive experience in finance and controlling as well as his strategic knowledge will play an important role for Dizlin Pharmaceuticals moving forward. We are excited to have him on board,” says Björn Velin, CEO of Dizlin Pharmaceuticals.

“I look forward to contribute and advance Dizlin Pharmaceuticals’ financial and business objectives that will support and further strengthen the company’s position as a pharmaceutical research company developing new innovative treatments for late stages of Parkinson´s disease,” added Daniel Mackey, Dizlin Pharmaceuticals’ Chief Financial Officer.

Michael Owens, who previously held the position as CFO will continue as Controller, thus ensuring a smooth transition, as well as supporting the company regarding external financial reporting matters.

For more information, please contact:

Björn Velin, CEO of Dizlin Pharmaceuticals AB, + 46 (0)76 879 2325, bjorn.velin@dizlin.se